Biomimetic glucose binding molecules


Carbometrics is a specialist supramolecular chemistry company having their core competency in the design, synthesis and derivatization of highly selective and robust synthetic small molecule receptors. Carbometrics aims to help people with diabetes to live more normal and longer lives


The company is developing highly potent glucose binding molecules; they are using their proprietary Biomimetic Glucose Binding Molecules (GBM) to develop a new glucose sensor chemistry what will enable market-leading Continuous Glucose Monitors (CGM).

Experienced management team from University of Bristol who sold the therapeutic rights of the underlying technology to Novo Nordisk for US$800M in 2018. Company retains the sole rights to develop the technology for advanced diagnostic applications in diabetes and other cardiometabolic diseases